eTable 2. Univariate and multivariate analysis of *PRKDC* and *TP53* loss with progression-free and overall survival following immune checkpoint-inhibitor-based therapies

	Progression-Free Survival			Overall Survival		
	HR	95% CI	p-value	HR	95% CI	p-value
Univariate Models (n = 62)						
PRKDC mutation	0.41	0.15-1.15	0.09	0.31	0.09-1.01	0.05
TP53 loss	2.23	1.20-4.15	0.01	2.54	1.29-5.01	0.01
PRKDC Mutation Multivariate Model (n = 62)						
PRKDC mutation	0.03	0.01-0.14	<0.001	0.10	0.02-0.47	0.003
ECOG PS	1.38	0.76-2.50	0.29	2.33	1.20-4.52	0.01
Previous lines of therapy	1.40	0.77-2.53	0.27	1.18	0.60-2.30	0.63
Regimen	15.38	5.02-47.13	<0.001	4.00	1.58-10.13	0.003
Visceral metastases	1.04	0.54-2.00	0.90	0.93	0.45-1.91	0.84
TP53 Loss Multivariate Model (n = 62)						
TP53 loss	2.28	1.18-4.37	0.01	2.43	1.19-4.98	0.02
ECOG PS	1.87	1.02-3.40	0.04	3.12	1.63-5.95	0.0006
Previous lines of therapy	1.48	0.84-2.61	0.18	1.28	0.67-2.44	0.45
Regimen	1.69	0.84-3.42	0.14	1.49	0.70-3.18	0.45
Visceral metastases	1.33	0.70-2.52	0.38	1.18	0.58-2.37	0.65

PRKDC nonsynonymous mutation: present vs. absent; *TP53* loss: tumors with both a *TP53* nonsynonymous mutation and a *TP53* one copy deletion vs. those without both; ECOG PS: ≥ 1 vs. 0; Previous lines of therapy: ≥ 1 vs. 0; Regimen: monotherapy vs. combination therapy; Visceral metastases: present vs. absent.

Abbreviations: ECOG PS: Eastern Cooperative Oncology Group performance status; HR; hazard ratio.